Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Solitary Fibrous Tumor, Pleural 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

selpercatinib 2pralsetinib 1entrectinib 1cediranib 1Taxes 1Nivolumab 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Cancer, Papillary × cediranib × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡